SHORT REPORTS
Terbutaline aerosol given through pear spacer in acute severe asthma
Pressurised aerosols are an ineffective way of giving bronchodilators in acute severe asthma. Less than 10%/ of a correctly administered dose from a standard pressurised aerosol reaches the bronchial tree,' and this may be reduced in acute severe asthma. Even under normal circumstances not more than 75%' of patients are able to use pressurised aerosols efficiently.2 Those who are unable to co-ordinate aerosol actuation with inhalation obtain benefit from the addition of an extension tube or spacer to the mouthpiece of the aerosol. 3 The pear spacer (Nebuhaler) is a plastic tube (750 ml volume) with a oneway valve that obviates the need for co-ordination. It is designed to contain the shape of the aerosol cloud when it leaves the actuator and increase the availability of the drug for inhalation. Newman et al4 showed that the deposition of radio aerosol in the whole lung is improved from 7 8%' to 11.5% with a tube spacer and to 13% with a pear spacer. 4 We used a pear spacer to deliver an aerosol bronchodilator (terbutaline) to patients with acute severe asthma and compared it with an electric nebuliser.
Patients, methods, and results
We studied 18 patients (11 women, seven men; age 15-67 years). All gave informed consent and satisfied the following: pulse rate 1 10/min or greater; forced expiratory volume in one second 25 % predicted or less; arterial oxygen pressure 9-3 kPa (70 mm Hg) or less; and forced expiratory volume in one second and forced vital capacity (best of three) measured on admission and 10 minutes later not varying by more than 10%. Patients who had received treatment with a bronchodilator within the previous two hours were excluded. Intravenous hydrocortisone 200 mg was given at the start of the study and oxygen administered throughout.
Patients were randomly allocated into two groups: one group received terbutaline 4 mg via an electric nebuliser (RTU 4; Medic Aid Ltd) followed after 30 and 60 minutes by two doses of terbutaline 2 mg (eight puffs) via a Nebuhaler; the second group received terbutaline 4 mg (16 puffs) via a Nebuhaler followed by two doses of 2 mg via a nebuliser 30 and 60 minutes later.
Forced expiratory volume in one second, forced vital capacity (Vitalograph dry spirometer), pulse, and blood pressure were measured on admission and 10 minutes later immediately before the first administration. Forced expiratory volume in one second, forced vital capacity, and pulse were recorded immediately after each administration and at 10-minute intervals until a plateau was reached. The blood pressure was recorded after 30 minutes and at the end of the study. The figure shows the mean baseline values after each administration of terbutaline.
The data were subjected to analysis of variance. Each treatment produced a significant rise in forced expiratory volume in one second and forced vital capacity (p < 0 01), but there was no significant difference between the two modes of administration. Pulse rate and blood pressure tended to fall throughout the study, and no adverse side effects were noted despite a total of 8 mg inhaled terbutaline being given. Mean baseline values and mean maximum values of heart rate, forced expiratory volume in one second (FEV,), and forced vital capacity (FVC) after each administration of terbutaline.
Comment
In severe asthma a bronchodilator given by any route may produce a fall in arterial oxygen partial pressure. Oxygen should be given before, during, and after its administration, as it was in this study.
Nebulised terbutaline produces just as effective bronchodilation as the intravenous drug in acute severe asthma. The use of beta-blockers in elderly patients with hypertension has been questioned owing to the increased incidence of heart failure in this age group. As our clinical impression at the outpatient hypertension clinic was that beta-blockers were well tolerated by elderly patients,' we decided to analyse the use and tolerability of betablockers in all patients over 65 who were being treated with these drugs, with special reference to the occurrence of heart failure.
Patients, methods, and results
A total of 301 patients aged over 65 years were being treated at the clinic. Two hundred and seventeen of these were aged from 65 to 69, 58 from 70 to 74, and 26 over 75.
Each year the doctors complete a computer record form for each patient with standardised questions about the case history, current antihypertensive treatment, side effects, and reasons for changes in treatment. Dyspnoea on exertion was diagnosed as heart failure if treatment with diuretics or digitalis was indicated.
Analysis of the prescription of beta-blockers in the different groups showed that three-quarters of the patients from 65 to 74 years and half of those aged over 75 were receiving beta-blockade. Analysis of the total treatment showed that 42 (14%) were receiving beta-blockers alone, 51 (17%) were receiving diuretics alone, and 193 (64%) were receiving combined treatment with beta-blockers and diuretics or other drug combinations; 15 (5%) were receiving no treatment. The mean dose for the two most commonly used beta-blockers was 189 mg/day for the beta,-selective metoprolol and 252 mg/day for the non-selective propranolol.
Analysis of the blood pressures showed good pressure control of 156/91 mm Hg in those aged 65-69, 166/94 mm Hg in those aged 70-74, and 174/93 mm Hg in those aged over 75.
Changes of the beta-blocker medication fell into three groups: discontinuation (21 patients (10%)), reduction of the dose (12 patients (5-5%)), and change to another type (49 patients (22.5 %))-for example, from a nonselective to a beta,-selective blocker (30 patients (14%)). The reasons for changing from a non-selective to a beta,-selective blocker were similar to those leading to withdrawal of beta-blockade (see table) .
Heart failure was diagnosed in 23 patients, of whom 16 (70%) were on beta-blockade in combination with diuretics, digitalis, or both.
Reason for withdrawal of beta-blockers 
Comments
This analysis showed that the beta-blockers were generally well tolerated in hypertensive patients over 65. The side effects and patterns of dosage resembled those seen in younger age groups. Heart failure was the reason for discontinuing the treatment in only one patient. Most of the side effects could be overcome by changing from a nonselective to a beta,-selective blocker or by reducing the dose.
Heart failure was diagnosed in 23 patients (11 %) and of these patients 16 (700o) were receiving beta-blockade in combination with diuretics or digitalis. In many of these patients symptoms of heart failure might have been due not to bad systolic contraction but to poor filling in stiff hearts. Even at heart rates as low as 120 beats/min the filling time becomes critical to the elderly heart.2 If the heart rate falls from 100 to 70 beats/min the diastolic filling time increases by 100% without the ejection time being affected.3 This favourable effect of beta-blockers on the diastolic filling is probably particularly important in the aged, stiff, hypertensive heart. Beta-blockers have been claimed to reduce the incidence of coronary heart disease.4 If good efficacy and tolerance is achieved with betablockers alone or in combination with other drugs in elderly patients with hypertension this could be important since the incidence of coronary heart disease is increasing with age in both men and women and since coronary heart disease is the most common end-point in hypertension. In chronic bronchitis the acini of mucous glands contain increased numbers of mucus-secreting cells. If Kulchitsky cells were similarly increased patients with chronic bronchitis might be expected to have raised circulating calcitonin concentrations. To test this hypothesis we measured plasma calcitonin concentrations in patients with mucopurulent disease and in a group of healthy, non-smoking controls. We also looked to see if there was some correlation between the plasma calcitonin concentrations and the cumulative numbers of cigarettes smoked during life.
Subjects, methods, and results
The study group comprised 45 men aged 36-78 years (mean 58.9) with chronic mucopurulent bronchitis.4 All were smokers or ex-smokers of cigarettes. Measurements were made during a quiescent phase of their illness when they were clear of acute infection and had stable blood gas values. None was taking any medication. Twelve healthy men aged years (mean 55-0 years) who had never smoked served as controls.
